News | Sutro Biopharma, Inc.

Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Poster

Society for Gynecologic Oncology (SGO) 2018 – STRO-002...

STRO-001 – Publication Highlights

STRO-001 – Publication Highlights Pan Pacific Lymphoma, 2018 HIGH FREQUENCY OF CD74 EXPRESSION IN B-CELL NON-HODGKIN’S LYMPHOMA (NHL) AND TARGETING WITH STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) WITH POTENT IN VITROCYTOTOXICTY AND IN...

Science and Platform Publication Highlights

Presentations

Science and Platform Publication Highlights Biotechnol Bioeng. 2011 Jul;108(7):1570-8. doi: 10.1002/bit.23103. Epub 2011 Mar 31. Microscale to manufacturing scale-up of cell-free cytokine production–a new approach for shortening protein production development...

Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

Press Releases

Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 — Two studies presented yesterday...

American Society of Hematology (ASH) 2017 – Oral Presentation

Presentations

American Society of Hematology (ASH) 2017 – Oral Presentation High Frequency of CD74 Expression in B-cell Non-Hodgkin’s Lymphoma (NHL) and Targeting with STRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent In Vitro Cytotoxicity and In Vivo...

Sutro Marks Two Drug Development Milestones

Press Releases

Sutro Marks Two Drug Development Milestones Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 — Sutro Biopharma has received a manufacturing milestone payment from Celgene and has...